Why an Oncology CoE? Because Complexity Has Outpaced Human Capacity.

A widening synthesis gap – the distance between the overwhelming volume of clinical data and a team’s ability to translate it into a winning strategy – is the real challenge in oncology today.

This gap is being driven by two forces working simultaneously.

The first force is cognitive.

Our environment has overwhelmed our ability to pay attention. Knowledge now doubles every 73 days in medicine.  It’s a structural condition that makes staying current physically impossible.  Information overload is now the operating baseline.

The second force is competitive.

There are thousands of novel therapies in development – ~800 CAR-Ts, ~300 ADCs across dozens of distinct targets. No team can meaningfully prioritize that field in a real-world commercial context. You can know a lot and still have no idea where to push.

The Central Premise of BioVid’s ONC CoE

BioVid’s oncology practice is organized around the idea that the tumor type produces the behavior.

Not the physician. The environment.

We call this ‘Tumor Worlds’ and it explains why a physician who is an aggressive “early adopter” in lung cancer is also a cautious, “wait-and-see” prescriber in pancreatic cancer. They didn’t change their personality; they moved into a different tumor landscape with different structural constraints.

Some Tumor Worlds are built for experimentation. Others carry decades of clinical failure, and that history functions like a standing verdict. We call it sealed pessimism. You won’t lose in these markets because your message is weak. You’ll lose because the verdict was decided before your drug existed.

Beyond Expertise: Mapping the Architecture

BioVid’s strategic CoE provides the structural view of these Tumor Worlds before you deploy capital. Think of it as an architectural audit of a treatment landscape to distinguish between:

• The Addressable vs. The Fixed: Which hurdles will respond to investment, and which are structural ceilings that should be subtracted from your forecast.
• The Systemic Filters: Understand how the community oncologist – who manages multiple “Worlds”, simultaneously (with about 12 minutes per patient per visit) – filters your data through their reality.

The Bottom Line

You don’t leverage a CoE to gain access to more experts; you leverage it to map the specific “World” your drug inhabits. Before you spend a dollar trying to change a physician’s mind, you must map the architecture of the room they are standing in.

Tumor Worlds is that architecture.  It’s what makes every downstream investment, from physician targeting to message development to market access strategy, more precise.

The syndicated framework launches later this year. If you’re building a commercial or market access strategy in oncology and want an early look, reach out to learn more about how Tumor Worlds maps to your specific indication.

Contact Meredith Jacobetz, PhD, at mjacobetz@biovid.com to stay ahead of the market reclassification.